Drug Information

Drug (ID: DG01143) and It's Reported Resistant Information

• Name: Butorphanol
• Synonyms: Butorphanol; Butorfanol; Butorphanol tartrate; Butorphanolum; 42408-82-2; levo-BC-2627; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL; Butorphanol (free base); (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; UNII-QV897JC36D; Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; CHEMBL33986; CHEBI:3242; QV897JC36D; l-BC 2627; DEA No. 9720; Morphinan-3,14-diol, 17-(cyclobutylmethyl)-; (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol; EINECS 255-808-8; Butorphanol (USAN/INN); Butorphanol [USAN:INN:BAN]; L-3,14-dihydroxy-N-(cyclobutylmethyl)morphinan; SCHEMBL3749; BIDD:GT0549; GTPL7591; DTXSID1022714; 42408-82-2 (free base); ZINC3812988; BDBM50240437; N-cyclobutylmethyl-3,14-dihydroxymorphinan; L-N-Cyclobutylmethyl-3,14-dihydroxymorphinan; C06863; D03197; J-504151; Q-200770; Q1185089; (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4,10-diol; (4bS,8aS,9R)-11-(cyclobutylmethyl)-5,6,7,8,9,10-hexahydro-8aH-9,4b-(epiminoethano)phenanthrene-3,8a-diol
• Indication:
  In total 1 Indication(s)
  Pain [ICD-11: MG30]; Approved; [1]
• Target: Opioid receptor delta (OPRD1); OPRD_HUMAN; [1]
• Formula: C21H29NO2
• IsoSMILES: C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O
• InChI: 1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
• InChIKey: IFKLAQQSCNILHL-QHAWAJNXSA-N
• PubChem CID: 5361092
• ChEBI ID: CHEBI:3242
• TTD Drug ID: D0X9RG
• DrugBank ID: DB00611

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Ovarian cancer [ICD-11: 2C73]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Transmembrane protein (TMEFF1) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Ovarian cancer [ICD-11: 2C73.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• In Vitro Model: LN308 cells; Brain; Homo sapiens (Human); CVCL_0394
• In Vitro Model: Primary pulmonary lymphoepithelioma-like carcinoma tissue; N.A.
• In Vitro Model: HCK1T cells; Ovary; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CCK8 assay; Colony Formation assay; Transwell assay; Flow Cytometry
• Mechanism Description: An important issue with compounds for treating ovarian cancer is the development of drug resistance and side effects. Butorphanol is a synthetic opioid. Opioids have been shown to promote or prevent tumor growth and metastasis. Butorphanol Inhibits the Malignant Biological Behaviors of Ovarian Cancer Cells via Down-Regulating the Expression of TMEFF1.

References

• Ref 1: Butorphanol Inhibits the Malignant Biological Behaviors of Ovarian Cancer Cells via Down-Regulating the Expression of TMEFF1 .Onco Targets Ther. 2020 Oct 28;13:10973-10981. doi: 10.2147/OTT.S244928. eCollection 2020. 10.2147/OTT.S244928